Table 1 ∣.
Baseline patient demographics and clinical characteristics
| Overall | |
|---|---|
| (n = 32) | |
| Age (years) | |
| Mean (s.d.) | 63.1 (6.95) |
| Median (minimum, maximum) | 64.0 (48.0, 74.0) |
| Age (years) | |
| 65+, n (%) | 15 (46.9) |
| <65, n (%) | 17 (53.1) |
| Race, n (%) | |
| White | 30 (93.8) |
| Black | 1 (3.1) |
| Asian | 1 (3.1) |
| Smoking history, n (%) | |
| Yes | 9 (28.1) |
| No | 23 (71.9) |
| Family prostate cancer history, n (%) | |
| Yes | 7 (21.9) |
| No | 25 (78.1) |
| PSA >10 ng ml–1 at diagnosis, n (%) | |
| Yes | 15 (46.9) |
| No | 17 (53.1) |
| Time from study entry to prostatectomy (weeks) | |
| Mean (s.d.) | 7.00 (0.392) |
| Median (minimum, maximum) | 6.86 [6.57, 8.29] |
| ECOG, n (%) | |
| 0 | 31 (96.9) |
| 1 1 (3.1) | |
| Body mass index (kg m2), n (%) | |
| Normal (18.5–24.9) | 6 (18.8) |
| Overweight (25.0–29.9) | 14 (43.8) |
| Obese (30.0+) | 12 (37.5) |
| Gleason-grade group at biopsy, n (%) | |
| 3 | 5 (15.6) |
| 4 | 11 (34.4) |
| 5 | 16 (50.0) |
| Previous therapy, n (%) | |
| No | 32 (100) |
| T stage, n (%) | |
| pT2 | 8.0 (25.0) |
| pT3a | 16.0 (50.0) |
| pT3b | 8.0 (25.0) |
| Patients with high-risk localized PCaa | |
| Yes, n (%) | 31.0 (96.9) |
| No, n (%) | 1 (3.1) |
| Patients with VHR localized PCab | |
| Yes, n (%) | 23.0 (71.9) |
| No, n (%) | 9 (28.1) |
a
High-risk group defined by National Comprehensive Cancer Network (NCCN) criteria as Gleason ≥8 or PSA>20 ng ml–1 or clinical T3 stage or higher.
b
VHR group defined as having at least one of the following: cT3b–cT4, primary Gleason pattern 5 on biopsy, >4 biopsy cores with a Gleason sum of 8–10 or 2–3 NCCN high-risk features.